Bullous Pemphigoid in Patients Receiving Immune Checkpoint Inhibitors and Psoriatic Patients — Focus on Clinical and Histopathological Variation - University of Regensburg Publication Server

URN to cite this document:: urn:nbn:de:bvb:355-epub-520373
DOI to cite this document:: 10.5283/epub.52037

Niebel, Dennis

; Wilsmann-Theis, Dagmar ; Bieber, Thomas ; Berneburg, Mark

; Wenzel, Joerg ; Braegelmann, Christine

Preview

License: Creative Commons Attribution 4.0
PDF - Published Version
(8MB)

Date of publication of this fulltext: 05 Apr 2022 04:52

Alternative links to fulltext:DOI Publisher

Details

Preview

Export bibliographical data

Abstract

Background: The most common autoimmune blistering disease, bullous pemphigoid (BP), shows an increased prevalence in psoriatic patients and oncologic patients undergoing immune-checkpoint blockade (ICB). Even though the same autoantigens (BP180/BP230) are detectable, it remains obscure whether clinical or histopathological differences exist between these different groups of BP patients. In this ...